Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes
Rhea-AI Summary
Jyong Biotech (Nasdaq: MENS) announced completion of the primary endpoint statistical analysis from its Phase II randomized, placebo-controlled trial of plant-derived drug MCS-8 (PCP) in Taiwan on Nov 20, 2025. The study enrolled >700 high-risk subjects across 20 hospitals with two years of treatment.
Key results vs placebo: 27.3% reduction in prostate cancer incidence and 17.1% reduction in high-grade prostate cancer (Gleason ≥7). Safety: two-year dosing showed no increase in adverse-event rates, no drug-related serious adverse events, and no negative effects on liver/kidney function or blood pressure. Lipids improved in the MCS-8 arm (LDL down, HDL up).
MCS-8 remains investigational and the company plans to pursue a multinational Phase III.
Positive
- 27.3% reduction in prostate cancer incidence versus placebo
- 17.1% reduction in high-grade prostate cancer (Gleason ≥7)
- No increase in adverse-event rates after two years of dosing
- No drug-related serious adverse events observed
- Significant lipid improvements: LDL decreased (P=0.018), HDL increased (P=0.003)
Negative
- MCS-8 remains an investigational drug and is not approved for commercial use
- Phase II was conducted only in Taiwan; results require multinational Phase III confirmation
News Market Reaction
On the day this news was published, MENS gained 12.44%, reflecting a significant positive market reaction. Argus tracked a peak move of +22.5% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $318M to the company's valuation, bringing the market cap to $2.88B at that time.
Data tracked by StockTitan Argus on the day of publication.
New Taipei City, Taiwan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8 (PCP).
The Company has completed the statistical analysis of the primary efficacy endpoints in its ongoing Phase II clinical trial conducted in Taiwan, following the randomized and placebo-controlled trial conducted to over 700 high-risk subjects enrolled into the Phase II clinical trial since its commencement. The data indicated that, compared with placebo, MCS-8 (PCP) demonstrated lower incidence rates of prostate cancer and high-grade prostate cancer (Total Gleason Score ≥ 7) with good overall tolerability, which lays an important foundation for potential future multinational Phase III clinical trials.
The MCS-8 (PCP) Phase II study was a randomized, placebo-controlled trial conducted across 20 hospitals in Taiwan with participation from over 130 urologists—representing more than one-tenth of all urologists nationwide. The trial enrolled more than 700 high-risk subjects, each receiving two years of treatment (either MCS-8 (PCP) or placebo).
Key findings showed the following:
- Primary efficacy endpoint:
Compared with placebo, the MCS-8 group indicated a27.3% reduction in prostate cancer incidence. - Secondary efficacy endpoint:
Based on maximum Gleason score, the incidence of high-grade prostate cancer (Total Gleason Score ≥ 7) showed a17.1% reduction compared with placebo.
Safety assessments also showed:
- Two-year administration of MCS-8 did not increase adverse event rates,
- No serious adverse events related to MCS-8 were observed,
- No negative impact on liver function (AST, ALT), kidney function (BUN, Creatinine), fasting glucose, or blood pressure (systolic/diastolic).
Moreover, in the placebo group, fasting glucose significantly increased (P = 0.022), and the triglycerides (TG), LDL, and HDL showed no significant differences. However, in the MCS-8 group, observed favorable lipid-modulating trends after two years of treatment compared with baseline:
- TG decreased (P = 0.05)
- LDL significantly decreased (P = 0.018)
- HDL significantly increased (P = 0.003)
The Company believes that these findings highlight the safety and tolerability of MCS-8 and suggest that there might be potential for future clinical studies in lipid management, atherosclerosis, and cardiovascular diseases.
Throughout the development of MCS-8 (PCP), the Company has adhered closely to U.S. FDA guidelines and standards, conducting rigorous scientific validation and clinical testing.
“These positive results affirm the potential of MCS-8 (PCP) as a compelling candidate for prostate cancer prevention,” said Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech. “With good safety and efficacy signals, we are now preparing for the next stage of development. Our objective is to initiate a global Phase III trial, in collaboration with international pharmaceutical companies to further validate its clinical potential.”
MCS-8 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction.
About Jyong Biotech Ltd.
Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.
For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Jyong Biotech Ltd.
ir@jyongbio.com
Investor Relations
WFS Investor Relations Inc.
Janice Wang
Email: services@wealthfsllc.com
Phone: +1 628 283 9214
FAQ
What did Jyong Biotech (MENS) announce on November 20, 2025 about MCS-8 Phase II results?
How large was the MCS-8 Phase II trial reported by MENS and where was it conducted?
What safety findings did Jyong Biotech report for MCS-8 (MENS)?
Did the MCS-8 Phase II trial show metabolic or lipid effects in the MENS announcement?
What are Jyong Biotech’s next steps for MCS-8 (MENS)?
